The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.
Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped Tuesday on a mixed third-quarter report, with the lion's share of its sales beat coming from its older ...
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...
TipRanks on MSN
Vertex price target lowered to $24 from $30 at BMO Capital
BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $24 from $30 and keeps a Market Perform rating on the ...
Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback